Les Turner ALS Foundation ALS Learning Series: Clinical Trials 101

Clinical Trials 101 featuring Benjamin Joslin, CCRC, Clinical Research Project Manager, Northwestern University Feinberg School of Medicine Tuesday, December 8 12pm CST Please join us for our second ALS Learning Series webinar, Clinical Trials 101, featuring Benjamin Joslin, CCRC, clinical research project manager with Northwestern University’s Feinberg School of Medicine on Tuesday, December 8, at 12pm CST. During this discussion, Benjamin will provide a basic understanding of ALS research and inform patients about how they can participate in clinical trials at our Lois Insolia ALS Clinic at the Les Turner ALS Center at Northwestern Medicine. He will go over the different aspects of clinical trials and their definitions, including phase I, II, III, IV trials and observational studies. He will also focus on prescreening procedures at Northwestern Medicine, placebo-controlled trials, and will highlight the breakthrough Healey Platform Trial. Finally, he will go over inclusion and exclusion criteria for enrollment in current and future clinical trials. The Les Turner ALS Center at Northwestern Medicine is among the global leaders in ALS research. Our clinical research encompasses a broad range of work, including biomarker studies, open label therapeutic studies, natural history studies and clinical trials. Whether participating in innovative clinical trials or long-term observation studies, our work offers hope to persons living with ALS and their caregivers while also uncovering new information about this disease. Benjamin is currently pursuing a graduate degree in public health from Northwestern University’s Feinberg School of Medicine. He has completed his coursework and is working on his thesis. While pursuing his graduate degree, he has been serving as clinical research coordinator for Dr. Senda Ajroud-Driss, director of our Lois Insolia ALS Clinic at Northwestern Medicine. Together, they have grown her portfolio of neuromuscular research, namely ALS research, hereditary amyloidosis (AMY-LOY-DOSIS), and peripheral neuropathy. Sign up to attend the Clinical Trials 101 webinar below!